Mepolizumab in allergic bronchopulmonary aspergillosis complicated by infection

Toru Hamada; Tomoya Katsuta; Kento Aibara; Shohei Nozu; Junya Nakamura; Haruka Kondo; Sayaka Tachibana; Koji Inoue; Norihiko Nakanishi; Tomonori Moritaka

doi:10.1016/j.rmcr.2023.101890

Mepolizumab in allergic bronchopulmonary aspergillosis complicated by infection

Respir Med Case Rep. 2023 Jul 16:45:101890. doi: 10.1016/j.rmcr.2023.101890. eCollection 2023.

Authors

Affiliation

¹ Respiratory Medicine, Ehime Prefectural Central Hospital, Matsuyama, Ehime, 790-0024, Japan.

Abstract

Allergic bronchopulmonary aspergillosis (ABPA) is an allergic reaction caused by the fungus Aspergillus, and it is often treated with steroids or antifungal agents. However, long-term use of these medications can lead to infections and drug interactions. We present the case of a 71-year-old woman with ABPA who was diagnosed with hepatitis B and active hepatitis C, and sputum analysis revealed the presence of bacteria. Oral steroids were initially administered, but the patient was switched to mepolizumab because of numerous infectious complications. The early introduction of mepolizumab is effective in patients with ABPA complicated by infectious diseases.

Keywords: Allergic bronchial aspergillosis; Mepolizumab; Numerous infectious complications.

Publication types

Case Reports